logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12252702 B1

PDFFull Text
Date of Patent:
Mar. 18, 2025

Filed:

Sep. 16, 2019

Recombinant poxviruses for cancer immunotherapy

Applicant:

Memorial Sloan Kettering Cancer Center, New York, NY (US);

Inventors:

Liang Deng, New York, NY (US);

Jedd Wolchok, New York, NY (US);

Stewart Shuman, New York, NY (US);

Taha Merghoub, New York, NY (US);

Ning Yang, New York, NY (US);

Yi Wang, New York, NY (US);

Gregory Mazo, New York, NY (US);

Peihong Dai, New York, NY (US);

Weiyi Wang, New York, NY (US);

Assignee:

MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US);

Attorneys:

ArentFox Schiff LLP

Daniel W. Clarke

Primary Examiner:

Peter J Reddig

Assistant Examiner:

Cheng Lu

Int. Cl.
CPC ...
C12N 15/86 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 16/28 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61K 9/0019 (2013.01); A61K 31/137 (2013.01); A61K 39/39 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 37/04 (2018.01); C07K 14/54 (2013.01); C07K 14/5434 (2013.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 14/70575 (2013.01); C07K 14/71 (2013.01); C07K 16/2818 (2013.01); C12N 7/00 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/585 (2013.01); C12N 2710/24134 (2013.01); C12N 2710/24143 (2013.01);
Abstract

Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of genetically engineered or recombinant poxviruses, including a modified vaccinia Ankara (MVA) virus comprising a deletion of E3L (MVAΔE3L) engineered to express OX40L (MVAΔE3L-OX40L), an MVA virus comprising a deletion of C7L (MVAΔC7L) engineered to express OX40L (MVAΔC7L-OX40L), a MVAΔC7L engineered to express OX40L and human Fms-like tyrosine kinase 3 ligand (hFlt3L) (MVAΔC7L-hFlt3L-OX40L), an MVA comprising a deletion of E5R (MVAΔE5R), a vaccinia virus comprising a deletion of C7L (VACVΔC7L) engineered to express OX40L (VACVΔC7L-OX40L), a VACVΔC7L engineered to express both OX40L and hFlt3L (VACVΔC7L-hFlt3L-OX40L), a VACV comprising a deletion of E5R (VACVΔE5R), a myxoma virus (MYXV) comprising a deletion of M31R (MYXVΔM31R), or combinations thereof, alone or in combination with other agents, as an oncolytic and immunotherapeutic composition.

Find Patent Forward Citations

Loading…